{"title":"[CAR T-cell therapy for malignant lymphoma].","authors":"Tomoyasu Jo, Yasuyuki Arai","doi":"10.11406/rinketsu.65.536","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in understanding of the pathogenesis of B-cell lymphoma have led to development of various novel targeted therapies. Among them, CD19-targeted chimeric antigen receptor (CAR) T-cell therapies for relapsed and refractory B-cell lymphomas have shown remarkable efficacy in clinical trials, and three CAR T-cell products are now available in Japan. Real-world evidence (RWE) has shown that these products can provide comparable efficacy to clinical trials in clinical practice, where CAR T-cells were administered in patients with wider range of backgrounds. This finding will certainly broaden the role of CAR T-cell therapies in the treatment of B-cell lymphoma. However, since about half of the patients treated with CAR T-cell therapy progress thereafter, there is an urgent need for risk stratification and optimized management of refractory cases. Here, we review the results of clinical trials and RWE of CAR T-cell therapy in B-cell lymphoma.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.65.536","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Advances in understanding of the pathogenesis of B-cell lymphoma have led to development of various novel targeted therapies. Among them, CD19-targeted chimeric antigen receptor (CAR) T-cell therapies for relapsed and refractory B-cell lymphomas have shown remarkable efficacy in clinical trials, and three CAR T-cell products are now available in Japan. Real-world evidence (RWE) has shown that these products can provide comparable efficacy to clinical trials in clinical practice, where CAR T-cells were administered in patients with wider range of backgrounds. This finding will certainly broaden the role of CAR T-cell therapies in the treatment of B-cell lymphoma. However, since about half of the patients treated with CAR T-cell therapy progress thereafter, there is an urgent need for risk stratification and optimized management of refractory cases. Here, we review the results of clinical trials and RWE of CAR T-cell therapy in B-cell lymphoma.
随着对 B 细胞淋巴瘤发病机制认识的不断深入,各种新型靶向疗法应运而生。其中,针对复发和难治 B 细胞淋巴瘤的 CD19 靶向嵌合抗原受体(CAR)T 细胞疗法在临床试验中显示出显著疗效,目前日本已有三种 CAR T 细胞产品上市。真实世界证据(RWE)显示,在临床实践中,这些产品可提供与临床试验相当的疗效,CAR T 细胞可用于具有更广泛背景的患者。这一发现无疑将扩大 CAR T 细胞疗法在 B 细胞淋巴瘤治疗中的作用。然而,由于接受CAR T细胞疗法治疗的患者中约有一半会在此后出现进展,因此迫切需要对难治性病例进行风险分层和优化管理。在此,我们回顾了CAR T细胞疗法治疗B细胞淋巴瘤的临床试验结果和RWE。